Serum lipopolysaccharide neutralizing capacity in ischemic stroke

• Verfasst von: Leskelä, Jaakko [VerfasserIn]
• Verfasst von: Safer, Anton [VerfasserIn]
• Verfasst von: Becher, Heiko [VerfasserIn]
• Verfasst von: Grau, Armin J. [VerfasserIn]
• Verfasst von: Palm, Frederick [VerfasserIn]
• Titel: Serum lipopolysaccharide neutralizing capacity in ischemic stroke
• Verf.angabe: Jaakko Leskelä, Milla Pietiäinen, Anton Safer, Markku Lehto, Jari Metso, Ernst Malle, Florian Buggle, Heiko Becher, Jouko Sundvall, Armin J. Grau, Pirkko J. Pussinen, Frederick Palm
• E-Jahr: 2020
• Jahr: February 21, 2020
• Umfang: 17 S.
• Fussnoten: Gesehen am 18.09.2020
• Titel Quelle: Enthalten in: PLOS ONE
• Ort Quelle: San Francisco, California, US : PLOS, 2006
• Jahr Quelle: 2020
• Band/Heft Quelle: 15(2020,2) Artikel-Nummer e0228806, 17 Seiten
• ISSN Quelle: 1932-6203
• DOI: doi:10.1371/journal.pone.0228806
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cholesterol
• Sach-SW: Endotoxemia
• Sach-SW: Endotoxins
• Sach-SW: Enzyme-linked immunoassays
• Sach-SW: Ischemic stroke
• Sach-SW: Lipids
• Sach-SW: Lipoproteins
• Sach-SW: Saliva
• K10plus-PPN: 1733328068

Abstract

Introduction: Periodontitis is associated with increased serum lipopolysaccharide (LPS) activity, which may be one mechanism linking periodontitis with the risk of cardiovascular diseases. As LPS-carrying proteins including lipoproteins modify LPS-activity, we investigated the determinants of serum LPS-neutralizing capacity (LPS-NC) in ischemic stroke. The association of LPS-NC and Aggregatibacter actinomycetemcomitans, a major microbial biomarker in periodontitis, was also investigated. Materials and methods: The assay to measure LPS-NC was set up by spiking serum samples with E. coli LPS. The LPS-NC, LPS-binding protein (LBP), soluble CD14 (sCD14), lipoprotein profiles, apo(lipoprotein) A-I, apoB, and phospholipid transfer protein (PLTP) activity, were determined in 98 ischemic stroke patients and 100 age- and sex-matched controls. Serum and saliva immune response to A. actinomycetemcomitans, its concentration in saliva, and serotype-distribution were examined. Results: LPS-NC values ranged between 51-83% in the whole population. Although several of the LPS-NC determinants differed significantly between cases and controls (PLTP, sCD14, apoA-I, HDL-cholesterol), the levels did not (p = 0.056). The main determinants of LPS-NC were i) triglycerides (β = -0.68, p<0.001), and ii) HDL cholesterol (0.260, <0.001), LDL cholesterol (-0.265, <0.001), PLTP (-0.196, 0.011), and IgG against A. actinomycetemcomitans (0.174, 0.011). Saliva A. actinomycetemcomitans concentration was higher [log mean (95% CI), 4.39 (2.35-8.19) vs. 10.7 (5.45-21) genomes/ml, p = 0.023) and serotype D more frequent (4 vs. 0%, p = 0.043) in cases than controls. Serotypeablity or serotypes did not, however, relate to the LPS-NC. Conclusion: Serum LPS-NC comprised low PLTP-activity, triglyceride and LDL cholesterol concentrations, as well as high HDL cholesterol and IgG against A. actinomycetemcomitans. The present findings let us to conclude that LPS-NC did not associate with stroke.